Lamotrigine PreSolicitation

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2D2-25-R-0002

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

-

SourceSAM
Documents1
The Defense Logistics Agency (DLA) Troop Support has issued a presolicitation notice for the procurement of Lamotrigine, a pharmaceutical product, under solicitation number SPE2D2-25-R-0002. This opportunity is classified under NAICS code 325412, which pertains to Pharmaceutical Preparation Manufacturing, and is further identified by Product Service Code (PSC) 6505, indicating a focus on drugs and biologicals. The primary objective of this procurement is to secure a reliable supply of Lamotrigine, a medication commonly used in the treatment of epilepsy and bipolar disorder, for federal use. The scope of the anticipated contract will likely encompass the manufacturing, packaging, and delivery of Lamotrigine in accordance with federal standards and requirements, ensuring the availability of this critical pharmaceutical to support the health and readiness of military personnel and other authorized recipients. DLA Troop Support, as the contracting entity, is a federal office responsible for providing a wide range of medical and pharmaceutical supplies to the Department of Defense and other federal agencies. The procurement is managed by the Medical Supply Chain division, with key points of contact being Nancy Fernandez ([email protected], 215-737-4955) and Jason C. Wray ([email protected], 215-737-0614). Interested parties are encouraged to direct any questions or requests for clarification to these individuals. The solicitation document is attached to the notice and provides detailed requirements, terms, and conditions for prospective offerors. Contractors should review the solicitation thoroughly to understand the specific deliverables, quality standards, and compliance obligations associated with the supply of Lamotrigine. While the presolicitation notice does not specify set-aside requirements or special considerations, contractors should monitor the solicitation for any updates regarding small business participation, evaluation criteria, or other procurement preferences. The notice was posted on November 25, 2024, and remains active, with responses due by January 9, 2025. Interested contractors should ensure timely submission of all required documentation in accordance with the instructions provided in the solicitation. This opportunity is well-suited for manufacturers with established capabilities in pharmaceutical preparation, particularly those experienced in producing and supplying medications to federal agencies. Contractors should assess their ability to meet the anticipated volume, quality, and regulatory requirements over the contract lifecycle before responding. For further details and to access the solicitation, contractors may visit the official notice page on SAM.gov at https://sam.gov/opp/ab01e774c7d54a82b86c5d99e8f70535/view.